Stop and think again. Changing perspectives with Champix (varenicline) in smoking cessation
Presenter(s)
Professor Keir Lewis Professor of Respiratory Medicine, Swansea University and Hon Consultant, Hywel Dda Health Board
Melanie Perry Secondary Care Specialist for Leicester City Stop Smoking Service
Abstract
Stop and think again. Changing perspectives with Champix (varenicline) in smoking cessation
This symposium is for Healthcare Professionals only and is organised and funded by Pfizer Ltd.
It is well known that smoking is the main cause of preventable illness and premature death contributing to a wide range of smoking related illnesses. It is also well known that licensed smoking cessation medications, alongside behavioural support, play an essential role in helping smokers to quit successfully.
During this symposium session, Professor Keir Lewis & Melanie Perry will provide an overview of the recently published data, the EAGLES study 1 – the largest randomised controlled trial of licensed smoking cessation medications that compares the neuropsychiatric safety of Champix and bupropion with placebo and nicotine patch in adult smokers with and without a history of psychiatric disorders. Keir and Melanie will share their thoughts on what the study means to them and what that could mean for you and for your patients. There will also be time to ask both speakers questions.
Click here for prescribing information about Champix (varenicline)
Source of funding: This symposium is organised and funded by Pfizer Ltd.
Please note that, under the law and the ABPI Code of Practice, Pfizer may only provide hospitality and/or promote its medicines to members of the healthcare professions and appropriate administrative staff. Therefore, no unqualified person (e.g. non-medical spouses, partners) may attend this Pfizer promotional symposium.
PP-CHM-GBR-0096 Date of Preparation: May 2016
References: 1. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers with and Without Psychiatric Disorders (EAGLES): A Double-blind, Randomised, Placebo-controlled Clinical Trial. Lancet. 2016 Apr 19:e1-e14.[Epub ahead of print].
